R&D Locations:St. Louis, MO

Worldwide Research and Development's St. Louis laboratories is focused in the areas Biologics and Indications Discovery. St. Louis is a Global Center of Emphasis of Biologics (large molecule medicines) research and specifically those that target proteins. The Mission of Pfizer's Indications Discovery Unit is to identify and develop novel indications for ongoing and discontinued Pfizer clinical compounds across multiple disease areas. Evaluating compounds through preclinical testing in disease models, as well as clinical assessment in relevant patient populations, our goal is to validate new uses for Pfizer clinical compounds through human Phase 2a testing. As part of our virtual model, we serve as a central switch for leveraging academic research and expertise at leading partner academic medical centers. With this rigorous evaluation we believe we can identify the right drug for the right patient.

In recent years St. Louis labs and colleagues are proud to have played a significant role in bringing Celebrex^® (for Arthritis), Inspra^® (for hypertension and congestive heart failure), Genotropin^® and Somavert^® (both for hormone disorders) to patients.

Currently the St. Louis groups are based at three locations (Chesterfield, Maryville, and the Cortex District.)